Zappasodi, Roberta

Publications

Sort by

Co-Author Network

selected publications

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6^th annual ImmunoRad conference. Oncoimmunology. 2023 Review GET IT
Times cited: 511
Targeting GITR in cancer immunotherapy - there is no perfect knowledge. Oncotarget. 2023 Academic Article GET IT
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. Journal for immunotherapy of cancer. 2023 Academic Article GET IT
Times cited: 1
Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Frontiers in oncology. 2023 Review GET IT
Times cited: 12
Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy. Frontiers in immunology. 2022 Editorial Article GET IT
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. The Journal of clinical investigation. 2022 Academic Article GET IT
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 5
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine. 2022 Academic Article GET IT
Times cited: 5
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Article GET IT
Times cited: 1
MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Science translational medicine. 2022 Academic Article GET IT
Times cited: 14
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. The Journal of experimental medicine. 2022 Academic Article GET IT
Times cited: 3
Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Academic Article GET IT
Times cited: 8
Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer immunology research. 2022 Academic Article GET IT
Times cited: 16
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature immunology. 2022 Review GET IT
Times cited: 79
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science advances. 2022 Academic Article GET IT
Times cited: 4
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in cell and developmental biology. 2022 Review GET IT
Times cited: 183
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research. Cancer immunology research. 2021 Academic Article GET IT
Times cited: 1
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8⁺ T cells in tumors. Immunity. 2021 Academic Article GET IT
Times cited: 152
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 3
To Go or Not to Go?-Targeting Tregs Traveling in Tumors. Cancer research. 2021 Comment GET IT
Times cited: 3
CTLA-4 blockade drives loss of T_reg stability in glycolysis-low tumours. Nature. 2021 Academic Article GET IT
Times cited: 130
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell reports. 2021 Academic Article GET IT
Times cited: 14
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
Times cited: 131
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Archives of biochemistry and biophysics. 2020 Academic Article GET IT
Times cited: 25
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 89
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020 Academic Article GET IT
Times cited: 242
In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. Methods in enzymology. 2019 Academic Article GET IT
Times cited: 3
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 28
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for immunotherapy of cancer. 2019 Article GET IT
Times cited: 2
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal for immunotherapy of cancer. 2019 Review GET IT
Times cited: 49
Rational design of anti-GITR-based combination immunotherapy. Nature medicine. 2019 Academic Article GET IT
Times cited: 137
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Academic Article GET IT
Times cited: 44
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 11
Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2018 Review GET IT
Times cited: 21
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 96
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Review GET IT
Times cited: 326
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Academic Article GET IT
Times cited: 679
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological oncology. 2017 Letter GET IT
Times cited: 16
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. Translational cancer research. 2016 Academic Article GET IT
Immunotherapy advances in uro-genital malignancies. Critical reviews in oncology/hematology. 2016 Review GET IT
Times cited: 20
Lymphoma Immunotherapy: Current Status. Frontiers in immunology. 2015 Review GET IT
Times cited: 293
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy. 2015 Review GET IT
Times cited: 3
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in cancer research. 2015 Review GET IT
Times cited: 40
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 5785
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood. 2015 Academic Article GET IT
Times cited: 30
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. Cancer research. 2014 Academic Article GET IT
Times cited: 57
Sialidase NEU4 is involved in glioblastoma stem cell survival. Cell death & disease. 2014 Academic Article GET IT
Times cited: 20
Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas. International journal of cancer. 2014 Academic Article GET IT
Times cited: 18
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 30
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012. Cancer immunology, immunotherapy : CII. 2013 Conference Paper GET IT
Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood. 2011 Academic Article GET IT
Times cited: 25
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer research. 2010 Academic Article GET IT
Times cited: 110
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. Cancer research. 2010 Academic Article GET IT
Times cited: 39
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2008 Academic Article GET IT
Times cited: 99
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica. 2008 Academic Article GET IT
Times cited: 53

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Tumor-metabolism-driven therapies to overcome TNBC immune resistance awarded by Breast Cancer Alliance Inc. Principal Investigator 2023 - 2025
Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy. awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2021 - 2024
SRA with BMS awarded by Bristol-Myers Squibb Company Principal Investigator 2021 - 2023
Targeting immune escape in Cluster 5 DLBCL awarded by AstraZeneca Pharmaceuticals LP Principal Investigator 2021 - 2023

Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Co-Investigator 2022 - 2027

Hypoxic incubator for physiological cell culture research awarded by National Institutes of Health, Office of the Director Key Personnel 2022 - 2023

more ...

less ...

Background

education and training

Ph.D., University of Milan (Italy) 2011
M.Sc., University of Bologna (Italy) 2005

Contact

full name

Roberta Zappasodi

primary email

roz4002@med.cornell.edu

VIVO Weill Cornell Medical College

Roberta Zappasodi Assistant Professor of Hematology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email